Turning T cell immunotherapeutic discoveries into cures
TechImmune, Inc. was founded in 2021 around the T-cell antigen platform technology exclusively licensed from the University of California, with the mission to develop novel strategies against coronaviruses to protect the public and economic health of individuals and societies globally.
Our approach is uniquely designed to target the root cause of disease by restoring functional anti-viral immunity, with the potential to deliver the first approved therapeutic intervention for Long COVID.
Explore Morepeople estimated to be affected by Long COVID globally.
of the U.S. population living with persistent symptoms.
clinical trials run, yet no effective therapy identified.
estimated economic cost each year, and growing.
A spinout of the Gavin S. Herbert Eye Institute, holding an exclusive license to a trio of coronavirus patents developed in the Laboratory of Cellular & Molecular Immunology.
Federal SBIR support for development of a universal vaccine against multiple coronavirus variants of concern, alongside private equity and philanthropic funding.
A seasoned team with a track record across Novavax, MedImmune, Allergan, Novartis and GSK Vaccines. Collectively, our officers and board members have launched dozens of companies and brought multiple healthcare products to market.
40+ years in vaccine science. Former Novavax Board Chairman and President of R&D at MedImmune.
Co-founder of Allergan, Inc., serving as CEO and Chairman for 30 years; former EVP at SmithKline Beckman.
30+ years in vaccine R&D. Former Global Head of External Research at Novartis and Head of Preclinical R&D (US) at GSK Vaccines.
Former Director of the U.S. CDC and Operation Warp Speed leader; active in Long COVID clinical research.
Professor of Immunology at UC Irvine and Director of the Laboratory of Cellular & Molecular Immunology; 125+ peer-reviewed papers.
30+ years in pharma R&D; former VP of Research at Allergan. PhD in Pharmacology, University of Pennsylvania.
Former Senior Advisor at HealthCare Ventures; former President of SmithKline & French and Allergan International.
Former Head of Research at Burroughs Wellcome and Director General of the ABPI; advisor on the G7 "100 Days" pandemic initiative.
25+ years in M&A and capital markets across family offices and the middle market. BS in Finance, USC.
Former President of R&D at Novavax; founder of IOMAI; author of 140+ publications.
Former CEO of Novavax; 50+ years in biopharma leadership. Former CEO of IOMAI and Procept.
TechImmune is developing a first-in-class T-cell-based immunotherapy that targets the root cause of Long COVID by clearing persistent SARS-CoV-2 reservoirs and restoring functional anti-viral immunity, with the potential to deliver the first disease-modifying treatment for Long COVID.
Unlike acute COVID-19 infections, Long COVID cannot be fully addressed with current vaccines or existing antiviral therapies, which do not clear persistent SARS-CoV-2 reservoirs or restore functional T-cell immunity. TechImmune's immunotherapy focuses on conserved non-spike viral antigens, boosting protective T-cell responses to clear those reservoirs and address the underlying cause rather than just the symptoms.
TechImmune was founded in 2021 around a T-cell antigen platform technology exclusively licensed from the University of California, Irvine, where it was invented by Professor Lbachir BenMohamed, PhD. The company holds an exclusive license agreement that includes patents in the United States.
An estimated 400 million people are affected by Long COVID globally, with roughly 7 percent of the U.S. population living with persistent symptoms. In the U.S. alone, 10 to 20 million people are affected, with 3 to 3.5 million projected to seek treatment for moderate to severe disease.
TechImmune is a preclinical-stage biotechnology company advancing its lead Long COVID immunotherapy toward IND-enabling studies in 2026 and first-in-human trials. The company is also developing a pan-coronavirus vaccine supported by an NIH/NIAID SBIR grant.
TechImmune is advancing toward IND-enabling studies and first-in-human trials and welcomes investment, partnering and scientific inquiries. The company can be reached by phone at +1 (949) 691-4350, by email at contact@techimmune.com, and at 5270 California Avenue, Suite 300, Irvine, CA 92617.
TechImmune is advancing toward IND-enabling studies and first-in-human trials. For investment, partnering and scientific inquiries, reach out below.
